Zentalis prices $80.5M stock offering to fund ovarian cancer drug
What's the deal? Zentalis Pharmaceuticals (Nasdaq: ZNTL) priced an underwritten public offering of 23,000,000 shares of common stock, raising roughly $80.5 million in gross proceeds. The San Diego clinical oncology company expects the offering to close on August 17, 2026.
The details: All shares are being offered by the company. Underwriters also have a 30-day option to buy up to 3,450,000 additional shares at the offering price, less discounts and commissions.
Who's in: TD Cowen, Guggenheim Securities, and Oppenheimer & Co. are joint bookrunners. H.C. Wainwright & Co. is a passive bookrunner, and Rodman & Renshaw is a manager.
What's the endgame? Zentalis is developing azenosertib, an investigational, potentially first-in-class WEE1 inhibitor, as a biomarker-driven treatment for ovarian cancer and other tumour types. It aims to offer a targeted, non-chemo, orally available medicine.
Where the money goes: Zentalis will combine the proceeds with existing cash to fund clinical trials, preclinical studies, regulatory filings, manufacturing, and its companion diagnostic. It also cited pre-commercial activities, capital expenditures, and working capital.
The signal: The raise ranks in the 31st percentile by amount among comparable rounds — a mid-sized capital injection typical of clinical-stage biotechs tapping public markets to push a lead candidate toward commercialisation.
Image credit: National Institutes of Health (NIH)
Read more: MarketScreener
